Tag Archives: David Steinberg

Jefferies Believes Amphastar Pharmaceuticals (NASDAQ: AMPH) Won’t Stop Here

Jefferies analyst David Steinberg reiterated a Buy rating on Amphastar Pharmaceuticals (AMPH – Research Report) on November 9 and set a price target of $26. The company’s shares opened today at $21.19, close to its 52-week high of $21.65. According

Jefferies Remains a Hold on Perrigo Company plc (PRGO)

In a report released today, David Steinberg from Jefferies reiterated a Hold rating on Perrigo Company plc (NYSE: PRGO), with a price target of $73. The company’s shares opened today at $69.01, close to its 52-week low of $67.69. According

Insys Therapeutics (INSY) Gets a Buy Rating from Jefferies

In a report released today, David Steinberg from Jefferies reiterated a Buy rating on Insys Therapeutics (NASDAQ: INSY), with a price target of $10. The company’s shares opened today at $7.39. According to TipRanks.com, Steinberg is a 4-star analyst with

Jefferies Keeps a Hold Rating on Teva Pharma (TEVA)

Jefferies analyst David Steinberg reiterated a Hold rating on Teva Pharma (NYSE: TEVA) today and set a price target of $21. The company’s shares closed yesterday at $21.61. According to TipRanks.com, Steinberg is a 4-star analyst with an average return

Menlo Therapeutics Inc was Downgraded to a Hold Rating at Jefferies

In a report released today, David Steinberg from Jefferies downgraded Menlo Therapeutics Inc (NASDAQ: MNLO) to Hold. The company’s shares opened today at $11.35, close to its 52-week low of $9.85. According to TipRanks.com, Steinberg is a 5-star analyst with

Jefferies Reiterates Their Buy Rating on scPharmaceuticals Inc

In a report released today, David Steinberg from Jefferies reiterated a Buy rating on scPharmaceuticals Inc (NASDAQ: SCPH), with a price target of $26. The company’s shares closed yesterday at $13.33. According to TipRanks.com, Steinberg is a 5-star analyst with